Commitment to Quality & Safety
2009 H1N1 Flu (Swine Flu)
Safety of Plasma-Derived Products
CSL Behring is committed to producing high-quality, safe and effective biotherapies to save lives and improve the quality of life for people with rare and serious medical conditions worldwide. Each step of the manufacturing process, from plasma donor to patient, reflects the company’s long-standing commitment to quality and safety.
At CSL Behring, we take the health of the people who use our lifesaving therapies very seriously. We meet or exceed the most stringent international standards for plasma product safety in accordance with regulatory agencies worldwide. Our dedication to collecting safe plasma and producing the highest quality products is well known in the plasma-protein therapies industry and throughout the patient communities we serve.
We believe our products have never been safer than they are today due to substantial investments in product safety, manufacturing facility enhancements, and research and development activities. In fact, during the past 25 years, the risk of virus transmission through plasma-derived products has been nearly eliminated.